-
Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval from the National Medical Products Administration (NMPA) for its anti-insomnia drug, Quviviq (daridorexant), co-developed with Swiss firm Idorsia Pharmaceuticals Ltd. The dual orexin receptor antagonist (DORA) is now cleared for testing in the treatment of…
-
Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese firm Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Under the terms of the agreement, Livzon will obtain all rights to Synergy Pharma’s HHT120 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. In…
-
Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services
•
China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with Japan-based Daiichi Sankyo (TYO: 4568). The collaboration aims to delve deeply into the fields of cardiovascular and cerebrovascular diseases, rheumatic bone surgery, and other areas. Additionally, the two companies will explore a patient-oriented, digitalization-driven healthcare…
-
Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study
•
Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B Streptococcus (GBS) vaccine candidate, GBS6, which is designed as a maternal immunization to protect infants against invasive GBS disease. The results reveal that the hexavalent vaccine generated a robust antigenic response in pregnant women, with…
-
US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes
•
The United States has published an update to its merger and acquisition guidelines, seeking public comment on potential changes to antitrust laws. These potential changes are a response to a recent surge in merger filings and increasing market concentration. The public comment period will remain open until September 18 this…
-
Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy
•
A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib, and Australia-based Telix Pharmaceuticals’s (ASX: TLX) targeted radiation therapy, TLX250 (177Lu-DOTA-girentuximab), has enrolled its first participant. This open-label dose escalation and dose expansion trial is designed to evaluate the safety profile, dosing, and activity of…
-
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National Medical Products Administration (NMPA) has granted another indication approval for its medication Sirturo (bedaquiline). The product is now approved for the treatment of adolescents aged 12-18 years and weighing ≥30kg with multidrug-resistant pulmonary tuberculosis (MDR-TB),…
-
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I clinical study for its recombinant Group B meningococcal vaccine (Escherichia coli), marking a significant step in assessing the vaccine’s safety, tolerability, and preliminary immunogenicity. This product is the first of its kind to enter clinical…
